Work

Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African–Americans with opioid use disorder

Year: 2018

Type: article

Source: The Pharmacogenomics Journal

DOI: 10.1038/s41397-018-0065-x

Authors: Richard C. Crist, Karran A. Phillips, Melody A. Furnari, Landhing M. Moran, Glenn A. Doyle, Laura F. McNicholas, James W. Cornish, Kyle M. Kampman, Kenzie L. Preston, Wade H. Berrettini

Institutions: University of Pennsylvania, National Institute on Drug Abuse, Philadelphia VA Medical Center

Language: English

Topic: Opioid Use Disorder Treatment

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: U.S. Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse

Awards: G1175036340, G1597174203, NIDA Clinical Trials Network - New York Node, Clinical and Genetic Study of Prescription Opioid Addiction, Western States Node of the National Drug Abuse Treatment Clinical Trials Network, G3635803607, Oregon/Hawaii Node, Clinical Trials Network, The role of the delta-opioid receptor gene, OPRD1, in opioid addiction treatment, Pharmacogenetics of Opioid Agonist Therapy, The National Drug Abuse Treatment Clinical Trials Network, G6609447057, G7514384629, Delaware Valley Node of the Clinical Trials Network, G8019308529, Clinical Trials Network: New England Node, Western States Node of the National Drug Abuse Treatment Clinical Trials Network

OpenAlex ID: W2898185173

FWCI: 2.857

Cites: 55

Cited by: 24

Related to: 10